Baratta Joseph sold $12.4M of BX

Baratta Joseph sold 100,000 shares of Blackstone Inc. (BX) at an average of $123.80 ($123.35–$124.13, $12.38M total) across 2 trades on 2026-09-18.

Original reporting
SEC EDGAR · Baratta Joseph
Published Sep 18, 2026, 9:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BX
Bearish
medium confidence
Mentioned
$BX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BXBearishLow
01

Why it matters

The disclosed sale provides fresh, material information about insider activity, offering a modest trading signal.

02

Market read

The filing introduces new insider activity for a large‑cap financial firm, yielding limited but actionable insight for short‑term traders.

03

What to watch

Potential tax‑loss harvesting or pre‑planned liquidity needs under the 10b5‑1 plan, though the filing states no pre‑arranged plan.

Relevance 7/10Novelty 7/10Timing: same-day

Background

Form 4 filings disclose insider transactions; director sales are publicly reported and can influence market perception.

Company-level read

Ticker impact

$BXBearishMedium confidence
Context

Director Baratta Joseph sold 100,000 Blackstone shares for $12.4M via open‑market transactions on 2026‑09‑18.

Expected impact

Possible modest downward pressure over the next few days, 1‑2% decline if market interprets as a negative signal.

Evidence & confidence

The sale size ($12.4M) is material for an insider but small relative to Blackstone's market cap; director sales often have limited predictive power, yet traders may react to the news.

Market effects

Minimal impact on the broader financial services sector; insider sales are company‑specific.

No significant regional effect; Blackstone trades globally but the filing is US‑focused.

Limited global relevance; only investors tracking Blackstone may adjust positions.

Counterpoint

The sale could be a routine portfolio rebalancing unrelated to company fundamentals, suggesting no need to short the stock.

Key entities

  • Blackstone Inc.

    Global investment firm (ticker BX) whose director sold shares.

  • Baratta Joseph

    Director of Blackstone who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BXMedAI 8/10

Blackstone Life Sciences announces $455M collaboration with Boston Scientific

Blackstone Life Sciences (BX) and Boston Scientific (BSX) are collaborating on a $455M project to develop the VITALYST heart pump system. This is the first co-funding deal between the two companies. The system aims to treat acute myocardial infarction cardiogenic shock by improving blood flow. BXLS sees potential in the technology to enhance current mechanical circulatory support devices.